Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16148529 | 0.91 | NR1I2 (0.76) | NR1I2KCNH2CYP3A4 | |
| SCHEMBL16148492 | 0.89 | NR1I2 (0.71) | NR1I2KCNH2CYP3A4PSIP1 | |
| SCHEMBL16148503 | 0.87 | NR1I2 (0.78) | NR1I2 | |
| SCHEMBL16158975 | 0.86 | NR1I2 (0.72) | NR1I2KCNH2CYP3A4PSIP1 | |
| SCHEMBL470403 | 0.85 | NR1I2 (0.85) | NR1I2KCNH2CYP3A4PSIP1 | |
| SCHEMBL16112616 | 0.84 | NR1I2 (0.48) | NR1I2KCNH2 | |
| SCHEMBL16112613 | 0.84 | NR1I2 (0.48) | NR1I2KCNH2 | |
| SCHEMBL459373 | 0.84 | NR1I2 (1.00) | NR1I2CYP3A4PSIP1 | |
| SCHEMBL459527 | 0.84 | NR1I2 (1.00) | NR1I2CYP3A4PSIP1 | |
| SCHEMBL470506 | 0.84 | NR1I2 (1.00) | NR1I2CYP3A4PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580431-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-28 | — | — | US | claimed |
| US-20160016960-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | US | claimed |
| EP-2970298-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014164467-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | claimed |
| US-9580431-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580431-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580431-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160016960-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016960-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016960-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2970298-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164467-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164467-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016960-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, RTF2, MAVS | NR1I2 3085/4885KCNH2 4551/4885CYP3A4 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.